This section contains scientific conference presentations &

peer reviewed publications of Viralytics' Oncolytic Virotherapy Technology

 

Scientific Conference Presentations

Combined Coxsackievirus A21 Oncolytic Virotherapy and Chemotherapy for the Treatment of Malignant Melanoma, Presented at the 6th Australian Society of Virology Meeting, 4-8 December 2011, Australia.

CAVATAKTM (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors, presented at the 8th International Congress of The Society for Melanoma Research, 9-11 November 2011, Tampa, Florida.

Oncolytic Activity of Coxsackievirus A21 (CAVATAK) in Human Lung Cancer: A Novel Targeted Anti-Cancer Strategy, presented at the 14th World Conference on Lung Cancer, 3-7 July 2011

Oncolytic Activity of Coxsackievirus A21 (CAVATAK) in Human Pancreatic Cancer, presented and the World Congress for Gastrointestinal  Cancers, Barcelona, Spain, 23 June 2011 

A Phase I, open label, cohort study of two doses of Coxsackievirus A21 given intratumorally in Stage IV melanoma, Presented at the American Society of Clinical Oncology, 5 June 2011 

Oncolytic activity of Coxsackievirus A21 (CAVATAK) in human pancreatic cancer, Presented at the 6th International Conference on Oncolytic Viruses as Cancer Therapeutics, April 2011

Coxsackievirus A21 as an oncolytic virotherapy agent against malignant glioma.  Presented at EUROPIC 2010: XVI Meeting in St Andrews, Scotland, September 2010

Immune response to an oncolytic human picornavirus, Coxsackievirus A21 (CAVATAK™) in patients with late stage melanoma. Presented at the Conference on Translational Cancer Research, Newcastle, NSW, Sept 2008

Coxsackievirus A21 oncolytic virotherapy as a novel treatment for malignant glioma. Presented at the Conference on Translational Cancer Research, Newcastle, NSW, Sept 2008

CAVATAKTM as an Oncolytic Virotherapy Agent for Human Cancers.  Presented at the 4th International Conference on Oncolytic Viruses as Cancer Therapeutics, Scottsdale, Arizona, USA, March 2007.

A Common-Cold Producing Virus with Anti-Cancer Properties Against Human Metastatic Breast Cancer. Presented at the 4th International Conference on Oncolytic Viruses as Cancer Therapeutics, Scottsdale, Arizona, USA, March 2007.

Low Pathogenic Enteroviruses as Novel Oncolytic Agents Against Human Prostate Cancer.  Presented at the Northern Lights EUROPIC XIVth Meeting of the European Study Group on the Moldeular Biology of Picornaviruses, November 2006.

Cosackievirus A21 as an Oncolytic Virotherapy Agent for Human Cancers.  Presented at the Northern Lights EUROPIC XIVth Meeting of the European Study Group on the Moldeular Biology of Picornaviruses, November 2006.

The Human Enterovirus, Coxsackievirus A21, exhibits Oncolytic Activity Across a Spectrum of Cancer Types.  Presented at AACR 96TH Annual Meeting, Anaheim, California, USA, October 2005.

 

Scientific Peer Reviewed Papers 

Gough G Au, Leone G Beagley, Erin S Haley, Richard D Barry, Darren R Shafren (2011) Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol J, 8:22
 

Kathryn A Skelding, Richard D Barry, Darren R Shafren (2010) Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest  New Drugs 
 

Erin S Haley, Gough G Au, Brian R Carlton et al. (2009) Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer. J Mol Med 87: 385-399
 

Linda J Berry, Gough G Au, Richard D Barry et al. (2008) Potent oncolytic activity of human enteroviruses against human prostate cancer. The Prostate 68: 577-87
 

Kathryn A. Skelding, Richard D. Barry, Darren R. Shafren (2009) Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat. 113: 21-30.


Gough G. Au, Lisa F. Lincz, Arno Enno, Darren R. Shafren (2007) Oncolytic Coxsackievirus A21 as a novel therapy for multiple myleoma.  Br J Haematol. 137: 133-141.
 

Gough G. Au, A. Michael Lindberg, Richard D. Barry, Darren R. Shafren (2005) Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol. 26: 1471-1476
 

Darren R. Shafren, Dianne Sylvester, E. Susanne Johansson, Ian G. Campbell, Richard D. Barry (2005)  Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer, 115: 320-328
 

E. Susanne Johansson, Li Xing, R. Holland Cheng, Darren R. Shafren (2004) Enhanced cellular receptor usage by a bioselected variant of Coxsackievirus A21. J Virol 78: 12603-12612
 

Nicole G. Newcombe, Leone G. Beagley, Dale Christiansen, Bruce E. Loveland, E. Susanne Johansson, Ken W. Beagley, Richard D. Barry, Darren R. Shafren (2004) Novel role for decay-accelerating factor in Coxsackievirus A21-mediated cell infectivity. J Virol. 78: 12677-12682
 

Nicole G. Newcombe, E. Susanne Johansson, Gough Au, A. Michael Lindberg, Richard D. Barry, Darren R. Shafren (2004)  Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection. J Virol. 78: 1431-1439.
 

Darren R. Shafren, Gough G. Au, Tam Nguyen, Nicole G. Newcombe, Erin S. Haley, Leone Beagley, E. Susanne Johansson, Peter Hersey, Richard D. Barry (2004) Systemic therapy of malignant human melanoma tumors by a common cold-producing virus, Coxsackievirus A21. Clin Cancer Res, 10: 53-60.


Nicole G. Newcombe, Per Andersson, E. Susanne Johansson, Gough G. Au, A. Michael Lindberg, Richard D. Barry, Darren R. Shafren (2003) Cellular receptor interactions of C-cluster human group A coxsackieviruses. J Gen Virol. 84: 3041-3050.


Darren R. Shafren, Douglas J. Dorahy, Rick F. Thorne, Richard D. Barry (2000)  Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 infection. J Gen Virol. 81: 889-894.
 

D. R. Shafren, J. Gardner, V. H. Mann, T. M. Antalis, A. Suhrbier (1999)  Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2.
J Virol. 73: 7193-7198.
 

Darren R. Shafren (1998) Viral cell entry induced by cross-linked decay-accelerating factor. J Virol. 72: 9407-9412.
 

Darren R. Shafren, Douglas J. Dorahy, Rick F. Thorne, Taroh Kinoshita, Richard D. Barry, Gordon F. Burns (1998)  Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity. J Immunol. 160: 2318-2323.
 

Darren R. Shafren, David T. Williams, Richard D. Barry (1997)  A decay-accelerating factor-binding strain of Coxsackievirus B3 requires the Coxsackievirus-Adenovirus receptor protein to mediate lytic infection of Rhabdomyosarcoma cells. J Virol. 71: 9844-9848.
 

Michael V. Agrez, Darren R. Shafren, Xinhua Gu, Karen Cox, Dean Sheppard, Richard D. Barry (1997)  Integrin αVβ6 enhances Coxsackievirus B1 lytic infection of human colon cancer cells. Virol. 239: 71-77.
 

Darren R. Shafren, Douglas J. Dorahy, Rebecca A. Ingham, Gordon F. Burns, Richard D. Barry (1997)  Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule-1 for cell entry. J Virol. 71: 4736-4743.
 

Darren R. Shafren, Douglas J. Dorahy, Sandra J. Greive, Gordon F. Burns, Richard D. Barry (1997)  Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by Coxsackievirus A21. J Virol. 71: 785-789.
 

Darren R. Shafren, Richard C. Bates, Michael V. Agrez, Robert L. Herd, Gordon F. Burns, Richard D. Barry  (1995)  Coxsackieviruses B1, B3, and B5 use decay-accelerating factor as a receptor for cell attachment.  J Virol. 69: 3873-3877.
   

Download required

Some files require Adobe Acrobat Reader to view. Download the free Adobe Acrobat Reader by clicking the button below - you will be taken to the Adobe website for more details.